Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
Anthonie J van der WekkenJ L KuiperA SaberM M TerpstraJ WeiT J N HiltermannE ThunnissenD A M HeidemanW TimensE SchuuringK KokE F SmitA van den BergH J M GroenPublished in: PloS one (2017)
No differences in survival were observed in patients with EGFR-T790M treated with afatinib compared to those without T790M. Tumors from patients who had progressive disease during afatinib treatment were enriched for mutations in genes involved in Wnt and PI3K-AKT pathways.